We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Peripheral Blood Smear Confirms Leishmaniasis

By LabMedica International staff writers
Posted on 05 Mar 2012
Peripheral buffy coat blood smears are a minimally invasive technique to diagnose the presence of the causative agents of visceral leishmaniasis (VL). More...


Buffy coat is the portion of blood that contains concentrates of white blood cells, including monocytes and platelets, and a smear can be examined for detection of amastigotes in suspected VL patients.

Laboratory staff at Rajshahi Medical College (Bangladesh) enrolled 112 VL patients in a prospective study during June 2009 to June 2010. Splenic aspiration was carried out for 66 patients by an experienced physician. The buffy coat was separated from the other blood components following the principle of concentration gradient separation by using Histopaque solution. Two good-quality smears prepared from buffy coat and stained with Leishman stain were examined under an oil immersion light microscope. Buffy coat DNA was extracted for a nested polymerase chain reaction (PCR) using the QIAamp DNA Blood Mini Kit.

The results of the study showed that 92% (103/112), 95.5% (107/112), and 100% (66/66) of VL patients were positive by buffy coat microscopy, buffy coat PCR, and spleen smear microscopy, respectively. Leishmania amastigotes were found by buffy coat microscopy in 93.5% (100/107) of those positive by buffy coat PCR and in 92.4% (61/66) of those positive for Leishmania amastigotes by spleen smear microscopy. Compared to spleen smear microscopy, the positivity rates of buffy coat PCR and buffy coat microscopy was comparable.

The buffy coat was prepared on Histopaque-1119 (Sigma-Aldrich, St. Louis, MO, USA) and the DNA extraction kit was from Qiagen (Hilden, Germany) The authors concluded that buffy coat smear was a promising confirmatory diagnostic tool for VL which can be used for point-of-care diagnosis in resource-limited health facilities. Splenic aspiration confirmation is risky and requires skilled personnel, and hence they are unavailable to the poor people in the regions of endemicity. Visceral leishmaniasis or Indian Kala-Azar is a vector-borne parasitic disease caused by an obligate intracellular hemoflagellate of the genus Leishmania and is fatal if it is not adequately treated. There are an estimated 500,000 new cases and 75,000 to 80,000 deaths per year, worldwide. The study was published in March 2012, in the Journal of Clinical Microbiology.

Related Links:
Rajshahi Medical College
Sigma-Aldrich
Qiagen


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.